Vera Alberto, Rivero Fernando, Salamanca Jorge, Alvarado-Casas Teresa, Alfonso Fernando
Instituto de Investigación Sanitaria (IIS-IP), Hospital Universitario de la Princesa, CIBERCV, Madrid, Spain.
Thromb Haemost. 2021 Jul;121(7):976-978. doi: 10.1055/a-1326-7028. Epub 2021 Feb 6.
The current article describes a 72-year-old woman who suffered an acute myocardial infarction due to plaque erosion (PE) 2 weeks after abemaciclib treatment onset due to advanced breast cancer. Abemaciclib is a cyclin-dependent kinase 4 and 6 inhibitor that has recently demonstrated efficacy and safety in advanced breast cancer. Of major concern, however, reported thromboembolic rates in randomized clinical trials testing this drug range from 0.6 to 5%. To the best of our knowledge this is the first thrombotic coronary side effect ever reported. We suggest that a treatment that increases thromboembolic risk, such abemaciclib, may have triggered PE in our patient, 15 days after abemaciclib initiation. New molecules are promising in cancer treatment; however, care must be paid to their potential cardiotoxic effects.
本文描述了一名72岁女性，在因晚期乳腺癌开始接受阿贝西利治疗2周后，因斑块侵蚀（PE）发生急性心肌梗死。阿贝西利是一种细胞周期蛋白依赖性激酶4和6抑制剂，最近已在晚期乳腺癌中显示出疗效和安全性。然而，主要令人担忧的是，在测试该药物的随机临床试验中报告的血栓栓塞率为0.6%至5%。据我们所知，这是首次报告的血栓性冠状动脉副作用。我们认为，像阿贝西利这样增加血栓栓塞风险的治疗方法，可能在阿贝西利开始使用15天后引发了我们患者的PE。新分子在癌症治疗中很有前景；然而，必须注意它们潜在的心脏毒性作用。
